Tegaserod (Zelnorm) for irritable bowel syndrome

Tegaserod (Zelnorm) for irritable bowel syndrome

Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal sec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American family physician 2004-01, Vol.69 (2), p.363
1. Verfasser: DeYoung, G Robert
Format: Artikel
Sprache:eng
Schlagworte:
Bowel disease
Female
Humans
Indoles - adverse effects
Indoles - economics
Irritable Bowel Syndrome - drug therapy
Medical treatment
Prescription drugs
Serotonin Receptor Agonists - adverse effects
Serotonin Receptor Agonists - economics
Women
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tegaserod (Zelnorm) is the first treatment approved by the US Food and Drug Administration for the short-term management of constipation-predominant irritable bowel syndrome (IBS) in women. A partial agonist of serotonin subtype-4 receptors, tegaserod stimulates peristalsis, increases intestinal secretion, and may alter associated pain. In contrast, alosetron (Lotronex) is available under restricted conditions of use for diarrhea-predominant IBS.
ISSN:0002-838X